WhichPeps

Delta sleep-inducing peptide

Neuropeptide

Also known as: DSIP· acronym
Sleep and neuroendocrin…
Generic peptide vial illustrationDelta sleep-inducing peptide
Evidence levelHuman evidence
Human evidenceLimited
Regulatory statusNot FDA-approved

What you need to know in 20 seconds

What is it?Neuropeptide
Research focusSleep and neuroendocrine research
Human evidenceHuman insomnia evidence is tiny, old and internally conflicting: a 1987 double-blind study reported substantial improvement, while a 1992 double-blind study found weak/inconsistent effects and considered major therapeutic benefit unlikely.
Regulatory statusNot FDA-approved; FDA lists DSIP/emideltide among substances with insufficient safety information.
Main limitationsReliable insomnia efficacy, chronic safety, modern subcutaneous use or a validated treatment regimen.
SafetyHuman safety data are sparse and dated; FDA says it lacks sufficient safety information for proposed compounded routes.
i
Human insomnia evidence is tiny, old and internally conflicting: a 1987 double-blind study reported substantial improvement, while a 1992 double-blind study found weak/inconsistent effects and considered major therapeutic benefit unlikely.

What the evidence actually supports

  • ✓DSIP should not be presented as an evidence-based sleep treatment.
  • ✓The correct page conclusion is 'conflicting small human evidence', not 'proven sleep peptide'.
  • ✓Pair the old insomnia literature with the current safety-information gap.

What is not established / key limitations

  • ×No robust replicated modern clinical benefit.
  • ×The later controlled study did not support a major therapeutic effect.
  • ×No adequate route-specific modern safety framework.

Selected study & evidence records

Double-blind DSIP study in chronic insomnia

1992 · Double-blind controlled clinical study · n=16

Some objective signals occurred, but effects were weak/inconsistent and investigators considered major therapeutic benefit unlikely.

Study detail → Primary source ↗

DSIP and 24-hour sleep-wake behaviour in severe chronic insomnia

1987 · Placebo-controlled, double-blind clinical trial · n=14

The study reported improved night sleep, daytime rest and performance, with effects persisting into the first placebo post-treatment night.

Study detail → Primary source ↗

Safety and unknowns

Human safety data are sparse and dated; FDA says it lacks sufficient safety information for proposed compounded routes.

Modern route-specific safety evidence is inadequate; FDA says it lacks sufficient safety information for nominated compounded emideltide/DSIP use.

Technical details

Mechanism / biologyProposed sleep/neuroendocrine modulator; mechanism remains uncertain.
Route / formulation boundaryOlder IV research does not validate modern nasal/injectable commercial products.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. Published human insomnia-study regimen. See dosing_evidence records for route, regimen, population, duration and source.
Identifiers & alternate namesDSIP · Emideltide

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.